This article reports on a clinical trial evaluating an occlusal splint with granisetron for myofascial pain in temporomandibular disorders, highlighting regulatory implications for device drug combinations.
Dated February 11, 2026, Mansoura University leads recruitment for NCT07401745, a study that pairs a medical device with a drug to address TMD related pain. Stakeholders in regulatory affairs, medical devices, and pharmaceutical development should note the study design and potential implications for future approvals.
What is being studied?
Intervention details
The study lists granisetron, lidocaine and an occlusal splint as the interventions for temporomandibular disorder related myofascial pain. The target population includes patients with TMD and related orofacial pain conditions. The sponsor is Mansoura University, and recruitment is ongoing as indicated in the source.
What therapies are included and how might they help?
Therapy components
The regimen combines a device occlusal splint with granisetron and lidocaine. The material lists these as interventions for TMD related myofascial pain. The description in the source text does not include detailed efficacy data; regulatory planning will require clarity on the intended use, performance and safety for this combined approach.
Who is sponsoring and what is the status?
Sponsor and recruitment status
Sponsors: Mansoura University. The trial is currently recruiting, focused on TMD or Orofacial Pain in the temporomandibular region. The ClinicalTrials.gov record number is NCT07401745, and the term parameter indicates a device focused inquiry.
What are regulatory implications?
Regulatory considerations
From a regulatory perspective the study represents a device and drug combination. The intended use, performance expectations and safety data would need clear definition for marketing authorization under MDR Annex XIV style as applicable. Statements attributed to the sponsor should be clearly labeled as such, and any claims would require robust evidence and appropriate approvals.
FAQ
- 1. What is this study about? The study evaluates an occlusal splint with granisetron and lidocaine for temporomandibular disorder related myofascial pain.
- 2. Who is sponsoring? Mansoura University sponsors the trial, with recruitment ongoing.
- 3. Where can I find more information? The trial is listed on ClinicalTrials.gov under NCT07401745, with a search term medical device.
Conclusion and implications
The study highlights a device and drug approach to TMD related pain and underscores the need for defined regulatory pathways and rigorous data on safety and performance. Readers in regulatory affairs and device development should monitor updates for potential guidance on such combinations.
Disclaimer: This article is for professional informational purposes only and does not constitute legal advice. It reflects the information available from the source text and does not verify regulatory approvals.
https://clinicaltrials.gov/study/NCT07401745?term=medical+device